The global biomarkers market was valued at approximately USD 77.6 billion in 2024 and is projected to witness substantial growth, reaching USD 244.8 billion by 2034, with a compound...
Company’s AD-Detect portfolio offers AB 42/40 and other plasma biomarker testing, alongside traditional cerebrospinal fluid and genetic tests, to provide robust offering in brain...
The pathological foundation of numerous acute and chronic neurological disorders, leading to enduring disability, lies in neuroaxonal damage and loss. The capability to easily...
The team acknowledges the challenges in realizing this potential, particularly the standardization of urinary biomarker assays and the expansion of the spectrum of diseases that...